busulfan has been researched along with Autosomal Recessive Chronic Granulomatous Disease in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Graft-versus-host disease prophylaxis consisted of cyclosporine A and, for unrelated donors, short course of methotrexate and anti-T-lymphocyte globulin." | 3.77 | Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience. ( Baran, J; Czogała, W; Goździk, J; Krasowska-Kwiecień, A; Pituch-Noworolska, A; Skoczeń, S; Wędrychowicz, A; Wiecha, O; Zembala, M, 2011) |
| "Busulfan was administered mainly intravenously and exceptionally orally from days -5 to -3." | 2.79 | Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. ( Ahmad, I; Albert, MH; Belohradsky, BH; Bredius, R; Fasth, A; Fernandes, JF; Fischer, A; Gaspar, HB; Gennery, A; Gruhn, B; Güngör, T; Haddad, E; Hassan, M; Hough, R; Kentouche, K; Lachance, S; Moshous, D; Rentsch, K; Resnick, IB; Schanz, U; Schlegel, PG; Seger, R; Shaw, PJ; Slatter, M; Stepensky, P; Stussi, G; Teira, P; Telles da Cunha, JM; Vermont, C; Veys, P, 2014) |
| "Exacerbation of infection during aplasia was observed in 3 patients; inflammatory flare at the infection site during neutrophil engraftment in 2: all 5 patients belonged to the subgroup of 9 with pre-existing infection." | 2.41 | Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. ( Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F, 2002) |
| " Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative and safe at the pediatric age but remains underperformed in adults." | 1.72 | Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency. ( Asnafi, V; Catherinot, É; Cheminant, M; Couderc, LJ; Fischer, A; Hermine, O; Jeljeli, M; Lanternier, F; Lortholary, O; Mahlaoui, N; Marçais, A; Moshous, D; Neven, B; Picard, C; Salvator, H; Suarez, F; van Endert, P, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Marçais, A | 1 |
| Mahlaoui, N | 1 |
| Neven, B | 1 |
| Lanternier, F | 1 |
| Catherinot, É | 1 |
| Salvator, H | 1 |
| Cheminant, M | 1 |
| Jeljeli, M | 1 |
| Asnafi, V | 1 |
| van Endert, P | 1 |
| Couderc, LJ | 1 |
| Lortholary, O | 1 |
| Picard, C | 1 |
| Moshous, D | 2 |
| Hermine, O | 1 |
| Fischer, A | 3 |
| Suarez, F | 1 |
| Jacoby, E | 1 |
| Adam, E | 1 |
| Hutt, D | 1 |
| Somech, R | 1 |
| Malkiel, S | 1 |
| Toren, A | 1 |
| Bielorai, B | 1 |
| Kapoor, R | 1 |
| Rastogi, N | 1 |
| Yadav, SP | 1 |
| Osumi, T | 1 |
| Tomizawa, D | 1 |
| Kawai, T | 1 |
| Sako, M | 1 |
| Inoue, E | 1 |
| Takimoto, T | 1 |
| Tamura, E | 1 |
| Uchiyama, T | 1 |
| Imadome, KI | 1 |
| Taniguchi, M | 1 |
| Shirai, R | 1 |
| Yoshida, M | 1 |
| Ando, R | 1 |
| Tsumura, Y | 1 |
| Fuji, H | 1 |
| Matsumoto, K | 2 |
| Shioda, Y | 1 |
| Kiyotani, C | 1 |
| Terashima, K | 1 |
| Onodera, M | 1 |
| Kato, M | 1 |
| Arnold, DE | 1 |
| Seif, AE | 1 |
| Jyonouchi, S | 1 |
| Sullivan, KE | 1 |
| Bunin, NJ | 1 |
| Heimall, JR | 1 |
| Güngör, T | 2 |
| Teira, P | 1 |
| Slatter, M | 2 |
| Stussi, G | 1 |
| Stepensky, P | 1 |
| Vermont, C | 1 |
| Ahmad, I | 1 |
| Shaw, PJ | 1 |
| Telles da Cunha, JM | 1 |
| Schlegel, PG | 1 |
| Hough, R | 1 |
| Fasth, A | 1 |
| Kentouche, K | 1 |
| Gruhn, B | 1 |
| Fernandes, JF | 1 |
| Lachance, S | 1 |
| Bredius, R | 1 |
| Resnick, IB | 1 |
| Belohradsky, BH | 2 |
| Gennery, A | 1 |
| Gaspar, HB | 1 |
| Schanz, U | 1 |
| Seger, R | 1 |
| Rentsch, K | 1 |
| Veys, P | 2 |
| Haddad, E | 1 |
| Albert, MH | 1 |
| Hassan, M | 2 |
| Oshrine, B | 1 |
| Morsheimer, M | 1 |
| Heimall, J | 1 |
| Bunin, N | 1 |
| Morillo-Gutierrez, B | 1 |
| Beier, R | 1 |
| Rao, K | 1 |
| Burroughs, L | 1 |
| Schulz, A | 2 |
| Ewins, AM | 1 |
| Gibson, B | 1 |
| Sedlacek, P | 1 |
| Krol, L | 1 |
| Strahm, B | 1 |
| Zaidman, I | 1 |
| Kalwak, K | 2 |
| Talano, JA | 1 |
| Woolfrey, A | 1 |
| Fraser, C | 1 |
| Meyts, I | 1 |
| Müller, I | 1 |
| Wachowiak, J | 1 |
| Bernardo, ME | 1 |
| Sykora, KW | 1 |
| Gennery, AR | 1 |
| Zhou, L | 1 |
| Dong, LJ | 1 |
| Gao, ZY | 1 |
| Yu, XJ | 1 |
| Lu, DP | 1 |
| Schuetz, C | 1 |
| Hoenig, M | 1 |
| Gatz, S | 1 |
| Speth, F | 1 |
| Benninghoff, U | 1 |
| Debatin, KM | 1 |
| Friedrich, W | 1 |
| Klaudel-Dreszler, MA | 1 |
| Kurenko-Deptuch, M | 1 |
| Wolska-Kusnierz, B | 1 |
| Heropolitanska-Pliszka, E | 1 |
| Pietrucha, B | 1 |
| Mikoluc, B | 1 |
| Gorczyńska, E | 1 |
| Ussowicz, M | 1 |
| Chybicka, A | 1 |
| Bernatowska, E | 1 |
| Kang, EM | 1 |
| Choi, U | 1 |
| Theobald, N | 1 |
| Linton, G | 1 |
| Long Priel, DA | 1 |
| Kuhns, D | 1 |
| Malech, HL | 1 |
| Goździk, J | 1 |
| Pituch-Noworolska, A | 1 |
| Skoczeń, S | 1 |
| Czogała, W | 1 |
| Wędrychowicz, A | 1 |
| Baran, J | 1 |
| Krasowska-Kwiecień, A | 1 |
| Wiecha, O | 1 |
| Zembala, M | 1 |
| Garming-Legert, K | 1 |
| Remberger, M | 1 |
| Ringdén, O | 1 |
| Dahllöf, G | 1 |
| Seger, RA | 1 |
| Blanche, S | 1 |
| Bordigoni, P | 1 |
| Di Bartolomeo, P | 1 |
| Flood, T | 1 |
| Landais, P | 1 |
| Müller, S | 1 |
| Ozsahin, H | 1 |
| Passwell, JH | 1 |
| Porta, F | 1 |
| Slavin, S | 1 |
| Wulffraat, N | 1 |
| Zintl, F | 1 |
| Nagler, A | 1 |
| Cant, A | 1 |
| Del Giudice, I | 1 |
| Iori, AP | 1 |
| Mengarelli, A | 1 |
| Testi, AM | 1 |
| Romano, A | 1 |
| Cerretti, R | 1 |
| Macrì, F | 1 |
| Iacobini, M | 1 |
| Arcese, W | 1 |
| Ariga, T | 1 |
| Kamani, N | 1 |
| August, CS | 1 |
| Douglas, SD | 1 |
| Burkey, E | 1 |
| Etzioni, A | 1 |
| Lischner, HW | 1 |
| Calviño, MC | 1 |
| Maldonado, MS | 1 |
| Otheo, E | 1 |
| Muñoz, A | 1 |
| Couselo, JM | 1 |
| Burgaleta, C | 1 |
| Leung, T | 1 |
| Chik, K | 1 |
| Li, C | 1 |
| Shing, M | 1 |
| Yuen, P | 1 |
| Thompson, EN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD[NCT03055247] | Phase 2 | 3 participants (Anticipated) | Interventional | 2015-11-06 | Recruiting | ||
| Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease[NCT00394316] | Early Phase 1 | 3 participants (Actual) | Interventional | 2006-10-30 | Terminated | ||
| Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency[NCT01306019] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2012-09-25 | Suspended (stopped due to Clones representing 10% or more of the subject patients myeloid lineage have been detected, no evidence of malignancy found.) | ||
| HLA-Matched, Peripheral Blood Stem Cell Transplantation Using Low Intensity Conditioning to Treat Patients With Chronic Granulomatous Disease Who Are Actively Infected[NCT00006417] | Phase 2 | 10 participants | Interventional | 2000-10-31 | Completed | ||
| Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care[NCT00023192] | Phase 3 | 60 participants | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for busulfan and Autosomal Recessive Chronic Granulomatous Disease
| Article | Year |
|---|---|
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2002 |
Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature.
Topics: Bone Marrow Transplantation; Busulfan; Child; Chromosomes, Human, X; Cyclophosphamide; Genetic Linka | 2003 |
[Gene therapy for primary immunodeficiency diseases].
Topics: Adaptor Proteins, Signal Transducing; Adenosine Deaminase; Busulfan; DNA-Binding Proteins; Genetic T | 2005 |
Bone marrow transplantation for chronic granulomatous disease: long-term follow-up and review of literature.
Topics: Bone Marrow Transplantation; Busulfan; Child; Coloring Agents; Cyclophosphamide; Female; Granulomato | 1999 |
4 trials available for busulfan and Autosomal Recessive Chronic Granulomatous Disease
| Article | Year |
|---|---|
A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning.
Topics: Adolescent; Allografts; Busulfan; Child; Child, Preschool; Granulomatous Disease, Chronic; Hematopoi | 2019 |
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; C | 2014 |
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Topics: Acute Disease; Adolescent; Adult; Allografts; Blood Platelets; Busulfan; Child; Child, Preschool; Di | 2016 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Topics: Adult; Aspergillosis; Busulfan; Chromosomes, Human, X; Combined Modality Therapy; Genetic Therapy; G | 2010 |
13 other studies available for busulfan and Autosomal Recessive Chronic Granulomatous Disease
| Article | Year |
|---|---|
Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency.
Topics: Adolescent; Adult; Busulfan; Child; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoi | 2022 |
Improved Outcome Following Busulfan-Based Conditioning in Children with Functional Neutrophil Disorders Undergoing Hematopoietic Stem Cell Transplant from HLA-Matched Donors.
Topics: Busulfan; Child; Child, Preschool; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoie | 2023 |
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; | 2021 |
Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Granulomatous Disease, | 2019 |
Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child, Preschool; Gr | 2015 |
Haploidentical hematopoietic stem cell transplantation for a case with X-linked chronic granulomatous disease.
Topics: Adolescent; Busulfan; Chromosomes, Human, X; Cyclophosphamide; Granulomatous Disease, Chronic; Hemat | 2017 |
Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Chimerism; Cyclophosphamide; Follow-Up Studies; Granu | 2009 |
Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC.
Topics: Antineoplastic Agents, Alkylating; Aspergillosis; Busulfan; Child, Preschool; Graft Survival; Granul | 2009 |
Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.
Topics: Adolescent; Antigens, CD; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease | 2011 |
Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
Topics: Adolescent; Age Factors; Anemia, Aplastic; Area Under Curve; Busulfan; Cyclophosphamide; Dose Fracti | 2011 |
Bone marrow transplantation in chronic granulomatous disease.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Granulomatous Disease, Chronic; Heterozygot | 1984 |
Bone marrow transplantation in chronic granulomatous disease.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Ch | 1996 |
Proceedings: Chronic granulomatous disease.
Topics: Adult; Busulfan; Child; Female; Granulomatous Disease, Chronic; Humans; Leukocytosis; Male; Phagocyt | 1974 |